vTv Therapeutics (FRA:5VT0) Non Operating Income: €-0.05 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
26 GF Score
Price €26.40
View Full Analysis

What is vTv Therapeutics Non Operating Income?

vTv Therapeutics FRA:5VT0 +3.94% 26 Non Operating Income is €-0.05 Mil as of Jun. 2026. GuruFocus rates FRA:5VT0 with a GF Score™ of 26/100.

Non Operating Income is income or expense that comes from miscellaneous sources. vTv Therapeutics's Non Operating Income for the three months ended in Jun. 2026 was €0.06 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.05 Mil.

vTv Therapeutics Non Operating Income Related Terms

vTv Therapeutics Non Operating Income Historical Data

* Premium members only.

The historical data trend for vTv Therapeutics's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

vTv Therapeutics Non Operating Income Chart

vTv Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.59 -2.52 -0.85 0.01 -0.12

vTv Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.03 -0.10 0.03 0.06
FRA:5VT0
26GF Score
vTv Therapeutics Inc FRA:5VT0
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

vTv Therapeutics Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of €-0.05 Mil mean?
vTv Therapeutics (FRA:5VT0) has a Non Operating Income of €-0.05 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on vTv Therapeutics and its competitors.
Is vTv Therapeutics' Non Operating Income too high?
vTv Therapeutics' current Non Operating Income is €-0.05 Mil. Overall, vTv Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Non Operating Income compare to VXRT and ENGN?
vTv Therapeutics' Non Operating Income of €-0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Non Operating Income is €-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
vTv Therapeutics (FRA:5VT0) has a current Non Operating Income of €-0.05 Mil. The current Non Operating Income is €-0.05 Mil. vTv Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For vTv Therapeutics (FRA:5VT0), the current Non Operating Income is €-0.05 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
26GF Score

Get the complete analysis for FRA:5VT0

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.40
Price